In December 2023, a wholly owned subsidiary of the Company entered into an Asset Purchase Agreement (APA) with GT Medical Technologies, Inc. (GT Medical) pursuant to which GT Medical acquired the Company’s Cesium-131 business and substantially all of the subsidiary’s assets related to that business, including equipment, certain contracts, inventory and intellectual property. The transaction closed in April 2024. For additional information, see Note 4, Discontinued Operations, of the 2025 Form 10-K.

Pursuant to the terms of, and subject to the conditions specified in, the APA, the Company’s subsidiary received 0.5% of GT Medical’s issued and outstanding capital stock on a fully diluted basis as of the closing of the transaction with GT Medical and has the right to receive, and GT Medical is obligated to pay, certain cash royalty payments of a low single digital percentage of annual net sales for approximately four years. During the second quarter of 2025, the Company recognized $0.2 million in royalties received pursuant to the GT Medical APA for the period from April 2024 to April 2025.

As of March 31, 2026, the GT Medical stock was valued at $0.2 million based on an updated valuation report prepared for GT Medical.